Compare SIND & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIND | NRIX |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2026 | 2020 |
| Metric | SIND | NRIX |
|---|---|---|
| Price | $13.24 | $23.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $18.40 | ★ $34.36 |
| AVG Volume (30 Days) | 84.5K | ★ 1.6M |
| Earning Date | 11-29-2026 | 10-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.26 |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | $786.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.26 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $10.03 | $9.71 |
| 52 Week High | $18.95 | $28.23 |
| Indicator | SIND | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 49.28 |
| Support Level | $12.72 | $22.48 |
| Resistance Level | $15.00 | $24.65 |
| Average True Range (ATR) | 0.77 | 1.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 37.61 | 87.05 |
Sinda Ltd is an exploration stage company focused on acquiring, exploring, and developing mineral concessions in Mexico. The company holds mining concessions and exploration and exploitation rights for a silver-gold project located in the Guanajuato silver belt of Mexico. Its principal asset is the Sinda Property, a silver project at the exploration stage.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.